NERV
NASDAQMinerva Neurosciences Inc
Price$4.75-0.31 (-6.13%)
01:30 PM06:45 PM
News · 26 weeks62+33%
2025-12-142026-06-07
Mix4190d
- SEC Filings20(49%)
- Insider10(24%)
- Other8(20%)
- Leadership2(5%)
- Analyst1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by CEO Luthringer Remy4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by Director Laghrissi-Thode Fouzia4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by SVP, CFO and Secretary Ahlholm Frederick W4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by Director Kupfer David4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by Director Hasler Hans Peter4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by Director Van Heek G Jan4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 4 filed by Director Kaul Inderjit4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- SECMinerva Neurosciences Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- PRMinerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline ProgramsBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the formation of its Scientific Advisory Board (SAB), fulfilling a commitment made in connection with the Company's PIPE financing announced on October 21, 2025. The SAB brings together distinguished researchers and clinicians with proven track records of advancing meaningful treatments in psychiatry and neuroscience. "The formation of this Scientific Advisory Board reflects our commitment to bringing the highest level of scientific rigor and clinical exp
- SECSEC Form 8-K filed by Minerva Neurosciences Inc8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECSEC Form 424B5 filed by Minerva Neurosciences Inc424B5 - Minerva Neurosciences, Inc. (0001598646) (Filer)
- PRMinerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare ConferenceBURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY. 2026 Jefferies Global Healthcare ConferenceFormat:Fireside chatDay/Time:Thursday, June 4 at 4:20 PM ETWebcast:Link here If you are interested in meeting with the Minerva team during the conference, please reach out to your Jefferies representative. A replay of the presentat
- SECSEC Form SCHEDULE 13G filed by Minerva Neurosciences IncSCHEDULE 13G - Minerva Neurosciences, Inc. (0001598646) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences IncSCHEDULE 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)
- SECSEC Form 10-Q filed by Minerva Neurosciences Inc10-Q - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECMinerva Neurosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- PRMinerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesConfirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug interaction concerns with roluperidone and olanzapine Roluperidone remains the only late-stage drug candidate for this high-need population BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported financial and business updates for the first quarter ended March 31, 2026. Business Updates Roluperidone - potenti
- SECSEC Form DEFA14A filed by Minerva Neurosciences IncDEFA14A - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECSEC Form DEF 14A filed by Minerva Neurosciences IncDEF 14A - Minerva Neurosciences, Inc. (0001598646) (Filer)
- INSIDERSEC Form 4 filed by O'Connor James Joseph4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 3 filed by new insider O'Connor James Joseph3 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- ANALYSTCitizens initiated coverage on Minerva Neurosciences with a new price targetCitizens initiated coverage of Minerva Neurosciences with a rating of Mkt Outperform and set a new price target of $14.00
- SECSEC Form PRE 14A filed by Minerva Neurosciences IncPRE 14A - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECSEC Form 8-K filed by Minerva Neurosciences Inc8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECMinerva Neurosciences Inc filed SEC Form 8-K: Regulation FD Disclosure8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
NERV FAQ
7 questionsWhat does Minerva Neurosciences Inc do?
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import...Where does NERV stock trade?
Minerva Neurosciences Inc (NERV) is listed on NASDAQ.What sector and industry is NERV in?
Minerva Neurosciences Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Minerva Neurosciences Inc go public?
Minerva Neurosciences Inc (NERV) completed its IPO in 2014.What are analysts saying about NERV?
Minerva Neurosciences Inc has had 2 recent analyst actions on file. The most recent action was from Citizens: Mkt Outperform with a $1400.00 price target on 2026-04-15. Recent price targets range from $500.00 to $1400.00.What companies are similar to NERV?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NERV side-by-side with any of them on Quantisnow.How can I track NERV on Quantisnow?
Quantisnow aggregates Minerva Neurosciences Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NERV to receive live email and push alerts on every new disclosure.